Journal of NeuroVirology

, Volume 21, Issue 6, pp 702–705

2nd International Conference on Progressive Multifocal Leukoencephalopathy (PML) 2015: JCV virology, progressive multifocal leukoencephalopathy pathogenesis, diagnosis and risk stratification, and new approaches to prevention and treatment

  • Andriani C. Patera
  • Scott L. Butler
  • Paola Cinque
  • David B. Clifford
  • Robert Elston
  • Robert L. Garcea
  • Eugene O. Major
  • Dejan Pavlovic
  • Ilse S. Peterson
  • Anne M. Ryan
  • Kenneth L. Tyler
  • Thomas Weber
  • on behalf of the PML Consortium
Meeting Report

Related online content

Since work described herein is primarily unpublished, titles of presentations are referenced below to allow readers to view the recorded presentations posted on www.pmlconsortium.org.

  1. Atwood W. Human polyoma virus receptor distribution. Session 1Google Scholar
  2. Berger J. PML associated with neurologic therapies. Session 3Google Scholar
  3. Buck C. Developing vaccines against JC polyomavirus. Session 4Google Scholar
  4. Clifford D. PML treatment/IRIS. Session 4Google Scholar
  5. DiMaio D. Cellular factors required for infection by small DNA viruses. Session 1Google Scholar
  6. Enquist L. Axons, the front line sensors of alpha herpes virus PNS invasion. Session 1Google Scholar
  7. Hirsch H. Testing JC and BK PyV antibody responses: why and how. Session 2Google Scholar
  8. Imperiale M. Trafficking of BKPyV to the nucleus. Session 1Google Scholar
  9. Legatie O. Biomarkers for JCV infection. Session 3Google Scholar
  10. Lindberg R. Molecular markers for a PML risk in natalizumab treated MS patients. Session 3Google Scholar
  11. Martin R. T cell immunity in PML and MS. Session 3Google Scholar
  12. McGavern D. T cell surveillance of the acute and persistently infected brain. Session 2Google Scholar
  13. Molloy E. PML associated with autoimmune and autoinflammatory diseases. Session 3Google Scholar
  14. Nath A. Antisense to JCV. Session 4Google Scholar
  15. Neu U. Polyomavirus structure, receptor interactions. Session 1Google Scholar
  16. Olsson T. Host genetics in the control of JCV infection. Session 3Google Scholar
  17. Ransohoff R. Blood brain barrier, CNS immune surveillance. Session 2Google Scholar
  18. Schneider-Hohendorf T. Natalizumab treatment is associated with increased anti-JCV antibody seroconversion. Session 3Google Scholar
  19. Shishido-Hara Y. JC viral inclusions in PML: PML-NBs. Session 2Google Scholar
  20. Werner M. Host Abelson-kinase inhibitors. Session 4Google Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2015

Authors and Affiliations

  • Andriani C. Patera
    • 7
  • Scott L. Butler
    • 1
  • Paola Cinque
    • 2
  • David B. Clifford
    • 3
  • Robert Elston
    • 4
  • Robert L. Garcea
    • 5
  • Eugene O. Major
    • 6
  • Dejan Pavlovic
    • 8
  • Ilse S. Peterson
    • 9
  • Anne M. Ryan
    • 10
  • Kenneth L. Tyler
    • 11
  • Thomas Weber
    • 12
  • on behalf of the PML Consortium
  1. 1.Inflammation and ImmunologyWorldwide Research and Development, Pfizer IncCambridgeUSA
  2. 2.Department of Infectious DiseasesSan Raffaele Scientific InstituteMilanItaly
  3. 3.Washington University School of MedicineSt. LouisUSA
  4. 4.Roche Pharma Research & Early DevelopmentRoche Products LimitedWelwyn Garden CityUK
  5. 5.Department of Molecular, Cellular, and Developmental Biology and the BioFrontiers InstituteUniversity of Colorado BoulderBoulderUSA
  6. 6.NINDSNIHDarnestownUSA
  7. 7.Infectious Disease and VaccinesMedImmune LLCGaithersburgUSA
  8. 8.Global Regulatory Affairs, Patient Safety and Quality AssuranceAstraZenecaGaithersburgUSA
  9. 9.PML Consortium SecretariatDrinker Biddle & Reath LLPWashingtonUSA
  10. 10.Drug Safety R&D, Worldwide Research and DevelopmentPfizer IncGrotonUSA
  11. 11.Department of NeurologyUniversity of Colorado School of MedicineAuroraUSA
  12. 12.Department of NeurologyMarienkrankenhausHamburgGermany

Personalised recommendations